Serologic allogeneic chimerism.
BACKGROUND
At least some transplanted livers secrete soluble human leukocyte antigens (sHLA) of donor phenotype into the body fluids of recipients. The individuals in whom this phenomenon occurs are by definition serologic allogeneic chimeras. Because an allogeneic transplanted liver may induce tolerance to itself and other organs in animals of the donor strain, and because maintenance of a soluble antigen in the circulation of any animal in sufficient quantity for a sufficient period generally leads to tolerance, this phenomenon may be biologically important. This study was performed to determine how common this phenomenon is and whether it occurs after transplantation of organs other than the liver.


METHODS
We studied 445 serum samples obtained from transplant recipients (liver, n=12; kidney, n=18; and heart, n=8) before and at various intervals after transplantation. All patients studied had allografts that had functioned for more than 1 year. We used an enzyme-linked immunosorbent assay to quantitate sHLA-A2 and sHLA-A1/A3/A11 (as a cross-reacting group). Donor and recipient combinations were selected in which measurable allotypes in donors were not present in recipients. In some instances, an additional allotype was present in a recipient but not in a donor.


RESULTS
All liver transplant recipients had detectable donor sHLA in their serum samples after transplantation. In 72% of kidney and 50% of heart transplant recipients, donor sHLA was found persistently in serum samples obtained after transplantation. Interestingly, all heart transplant recipients of HLA-A3, but none of HLA-A2, had detectable donor sHLA in their serum samples, a finding that may be due to technical reasons. High and stable serum concentrations of donor sHLA characterize long-term stable allograft function.


CONCLUSIONS
Donor sHLA is produced by all transplanted livers, most transplanted kidneys, and at least half of (but probably more) transplanted hearts. The hypothesis that donor sHLA may be tolerogenic to liver transplants can be expanded to include kidney and heart transplants.
McDonald
J C
JC
Department of Surgery, Louisiana State University Medical Center, Shreveport 71130, USA.
Adamashvili
I
I
Zibari
G B
GB
Aultman
D F
DF
Mancini
M C
MC
McMillan
R W
RW
Gelder
F B
FB
D000911:Antibodies, Monoclonal; D003602:Cytotoxicity, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D015234:HLA-A Antigens / Q000097:blood*; D015789:HLA-A2 Antigen / Q000097:blood; D015791:HLA-A3 Antigen / Q000097:blood; D016027:Heart Transplantation / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007126:Immunoglobulin Allotypes / Q000097:blood; D007519:Isoantigens / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology*; D016031:Liver Transplantation / Q000276:immunology*; D013997:Time Factors; D014019:Tissue Donors; D018183:Transplantation Chimera; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D015234:HLA-A Antigens; D015789:HLA-A2 Antigen; D015791:HLA-A3 Antigen; D007126:Immunoglobulin Allotypes; D007519:Isoantigens